Send us a text

June 1, 2022 RJ podcast: Three Chippy Topics in Prostate Cancer. In this month’s podcast, two Genitourinary section editors, Dr. Alison Tree, consultant clinical oncologist at The Royal Marsden and Honorary Faculty at the Institute of Cancer Research, and Dr. Daniel Spratt, Chairman and Professor of Radiation Oncology at University Hospitals Seidman Cancer Center and Case Western Reserve University, join Editor-in-Chief Dr. Sue Yom to review three articles addressing cutting-edge issues in prostate cancer. The group discusses the new oral gonadotropin-releasing hormone antagonist relugolix ("An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer" at https://www.redjournal.org/article/S0360-3016(21)03240-5/fulltext), the future of MRI-based radiation dose escalation to the dominant intraprostatic lesion ("SABR for High-Risk Prostate Cancer - A Prospective Multilevel MRI-Based Dose Escalation Trial" at https://www.redjournal.org/article/S0360-3016(21)03047-9/fulltext), and an analysis from the United Kingdom’s CHHiP trial comparing disease outcomes and sexual function among patients receiving bicalutamide versus luteinizing hormone-releasing hormone analogues ("Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial" at https://www.redjournal.org/article/S0360-3016(21)03433-7/fulltext).